Benefits
Oxidative-stress markers in a 12-week placebo-controlled trial
In 60 adults with type 2 diabetes, 250 mg or 500 mg of an aqueous extract twice daily for 12 weeks improved blood vessel function versus placebo, and the abstract reports that the other markers measured, including malondialdehyde (a lipid oxidation marker) and glutathione, also improved. The higher dose did best. It is one small single-site trial.
Anti-glycation activity, so far only in the laboratory
In test-tube work, a T. chebula fruit extract blocked the formation of advanced glycation end-products (AGEs), compounds formed when sugars bind to proteins, and reduced protein cross-linking in a dose-dependent way. It also lowered AGE-triggered oxidative stress in cultured human blood vessel cells. No human trial has measured AGE levels after taking T. chebula.
Knee comfort during activity in overweight adults
In 105 overweight adults with knee discomfort during activity, 250 mg or 500 mg twice daily of AyuFlex, a branded standardized extract with its own profile, improved a knee comfort and function score more than placebo over 84 days. Knee discomfort ratings, walking distance and soreness after exercise also improved more than placebo, while knee mobility and low back ratings did not. The maker funded the trial. A single 1,000 mg dose also raised pain thresholds in 12 healthy men.
Facial oiliness and wrinkle appearance in women
In 38 overweight premenopausal women, 250 mg of a standardized extract twice daily for 8 weeks lowered wrinkle severity about 4% versus a 3.9% rise on placebo. In a subgroup of 15 with oily skin at the start, forehead oil output fell 33% versus a 29% rise on placebo. The extract's maker funded the study and employs one author.
Serum uric acid levels over 24 weeks
In 110 adults with high serum uric acid randomized to five arms, 500 mg of a standardized extract twice daily for 24 weeks lowered uric acid by about 16% (7.76 to 6.42 mg/dL), versus a 7% rise on placebo, with the drop significant from week 4. The related fruit Terminalia bellerica lowered it more, and 22% on T. chebula reached 6 mg/dL or less.
Digestive use: human data come from triphala, not the fruit alone
A PubMed search finds no placebo-controlled trial of T. chebula alone on bowel habits or gut bacteria. In triphala, the three-fruit blend that contains it, 2,000 mg a day for 4 weeks in 31 healthy adults changed no bacterial group uniformly; both herb groups had fewer Rikenellaceae and a trend toward more Akkermansia. Triphala has its own ingredient profile.
Blood vessel function and blood lipids
In 60 adults with type 2 diabetes, 12 weeks of an aqueous extract improved endothelial function, the main outcome, versus placebo, and the abstract reports better lipid profiles too. In 90 people with high cholesterol, triphala plus guggul for 3 months was no better than placebo: total cholesterol fell 3.3% versus 1.9%, and LDL fell about 5% in both groups.
Fasting glucose and HbA1c in human trials
Chebulagic acid from the fruit blocks a carbohydrate-digesting enzyme (alpha-glucosidase) in lab tests. In the one placebo-controlled trial of the extract alone, in 60 adults with type 2 diabetes, HbA1c was among markers the abstract reports as improved, without values. A capsule pairing T. chebula with two resins lowered fasting glucose but not HbA1c. It is not a substitute for diabetes care.
Mechanism of action
Glycation inhibition in laboratory models
A methanol extract of the fruit containing 2.7% chebulic acid inhibited AGE formation and glycation-driven protein cross-linking in cell-free tests, with 1,000 micrograms/mL performing about as well as the reference inhibitor aminoguanidine. In cultured human endothelial cells it reduced AGE-induced reactive oxygen species and monocyte adhesion. No human tissue measurements exist.
Nrf2 antioxidant signaling in cell studies
In human liver cells (HepG2) exposed to an oxidant, chebulic acid raised cell glutathione, increased heme oxygenase-1 activity and moved the transcription factor Nrf2 into the nucleus, switching on its target antioxidant genes in a dose-dependent way. These are cell results; whether supplement doses do this in people has not been measured.
Alpha-glucosidase inhibition in enzyme assays
Chebulagic acid isolated from the fruit was a reversible, non-competitive inhibitor of maltase, an intestinal alpha-glucosidase, with stronger action on the maltase-glucoamylase complex than on sucrase-isomaltase. None of the human trials cited here measured post-meal glucose, so the practical effect in people is unknown.
Galloyl groups bind dietary iron
In human iron absorption studies, gallic acid and tannic acid (a hydrolyzable tannin built from gallic acid units) cut nonheme iron absorption from a test meal in a dose-related way: 5 mg of tannic acid lowered it by 20% and 100 mg by 88%. T. chebula tannins share these galloyl groups, though the fruit itself was not tested.
Clinical trials
Randomized, double-blind, placebo-controlled trial over 84 days with a two-week placebo lead-in: standardized aqueous fruit extract 250 mg or 500 mg twice daily versus placebo; sponsored by the extract's maker, Natreon; registered NCT02589249. (Lopez et al. 2017, BMC Complement Altern Med)
105 apparently healthy overweight adults aged 35 to 70 with knee discomfort during activity but none at rest.
Against placebo at day 84, the combined extract groups improved the modified Knee Injury and Osteoarthritis Outcome Score (p = 0.023). Change scores for knee discomfort with activity (p < 0.001), whole-body joint function (p = 0.029) and 6-minute walk distance (p = 0.022) also improved more than placebo (the abstract words these as relative to baseline), while knee mobility and low back scores did not separate from placebo. Safety blood markers stayed within normal limits; a few mild or moderate side effects were reported in all three groups at similar rates, and none were serious. The two doses performed similarly for most outcomes.
Prospective, randomized, double-blind, placebo-controlled study at Nizam's Institute of Medical Sciences, Hyderabad, India: aqueous extract 250 mg or 500 mg twice daily versus placebo for 12 weeks. (Pingali et al. 2020, Phytother Res)
60 adults with type 2 diabetes randomized to three arms.
Endothelial function (reflection index) improved against placebo at both doses (250 mg: -2.55 ± 1.82%; 500 mg: -5.21 ± 2.41%; placebo: +1.40 ± 2.11%). The abstract states that the other cardiovascular risk markers measured (nitric oxide, malondialdehyde, glutathione, high-sensitivity CRP, HbA1c and lipid profile) were also significantly improved versus placebo, without giving their values, and that 500 mg twice daily worked best. Small, single site, not independently repeated.
Randomized, double-blind, placebo- and positive-controlled pilot trial in Hyderabad, India: T. chebula extract (AyuFlex) 500 mg twice daily, T. bellerica extract 250 mg or 500 mg twice daily, a prescription positive control or placebo for 24 weeks; study capsules supplied by Natreon. (Usharani et al. 2016, Clin Pharmacol)
110 adults with hyperuricemia (high serum uric acid) randomized across five arms.
On T. chebula, serum uric acid fell from week 4 compared with baseline (p<0.01), while it rose on placebo (p<0.05); levels leveled off after 16 weeks. The T. chebula reduction was about half that of T. bellerica 500 mg. By week 24, 22.2% on T. chebula reached 6 mg/dL or less, versus none on placebo. One person on T. chebula had mild gastrointestinal intolerance, and no one withdrew because of adverse events.
Prospective, randomized, double-blind, placebo-controlled trial in the Sacramento area, registered NCT04597502: standardized fruit extract (Synastol TC) 250 mg twice daily or placebo for 8 weeks; funded by Sytheon, the extract's maker, and one author is a Sytheon employee. (Chakkalakal et al. 2023, J Clin Med)
Overweight (BMI 25 to 35), otherwise healthy premenopausal women; 38 completed (21 extract, 17 placebo).
Across all 38 women, wrinkle severity fell 4.3% on the extract versus a 3.9% rise on placebo, and cheek redness fell 2.2% versus a 1.5% rise (both p<0.05); forehead and cheek oil output rose less than on placebo. In a sub-analysis of 15 women with baseline forehead sebum above 80 micrograms/cm2, sebum fell 33% versus a 29% rise on placebo at 8 weeks (p<0.01 in the abstract, p<0.05 in the full text). Small, short and maker-funded; not independently repeated.
Randomized, double-blind, placebo-controlled crossover with a washout between treatments: one 1,000 mg dose (two 500 mg capsules) of a standardized aqueous extract or placebo, tested 3 hours later with a mechanical pressure device; capsules supplied by Natreon. (Pokuri et al. 2016, J Anaesthesiol Clin Pharmacol)
12 healthy men aged 18 to 40.
Compared with placebo, the extract raised pain threshold force and time (by 20.8% and 21.0%) and pain tolerance force and time (by 13.4% each; p<0.001). No adverse reactions were reported. A one-dose laboratory pain model in healthy volunteers says nothing direct about daily joint comfort.